Regeneron Pharmaceuticals and Telix Pharmaceuticals have announced a strategic collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies, marking a significant expansion into precision oncology.

 

The partnership brings together Regeneron’s biologics and antibody engineering capabilities with Telix’s radiopharmaceutical development platform, global manufacturing strength, and supply chain infrastructure. 

 

The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio, including candidates derived from its VelocImmune mouse platform. Alongside therapeutics, the alliance will also develop companion radio-diagnostics designed to improve patient selection and track treatment response.

 

“At Regeneron, we follow the science to determine the best therapeutic approach for each disease, continuously expanding our toolbox of treatment modalities – from monoclonal and bispecific antibodies to cell therapies and beyond. 

 

"Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need,” said John Lin, Senior Vice President of Oncology & Antibody Technology Research at Regeneron.

 

The companies said the collaboration will also explore how radiopharmaceuticals could be deployed alone or in combination with Regeneron’s existing immunotherapy pipeline, including its PD-1 inhibitor, particularly in hard-to-treat cancers such as lung cancer.

 

“Telix brings deep expertise in radiopharmaceutical development and infrastructure that complements Regeneron’s antibody technologies and oncology portfolio,” said Israel Lowy, Senior Vice President, Clinical Development Unit Head, Oncology at Regeneron. 

 

“Regeneron is excited to enter the targeted radiopharmaceuticals space and explore the utility of these agents either as monotherapy or rationally combined with our immunotherapy platform, particularly in areas of high unmet patient need such as lung cancer, where our PD-1 inhibitor is a global standard of care.”

 

Telix framed the deal as a major step toward advancing “next-gen” biologics-driven radiopharmaceuticals.

 

“The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true ‘next gen’ biologics-based radiopharmaceuticals can potentially do for patients,” said Christian Behrenbruch, Managing Director and Group CEO at Telix. 

 

“We are well positioned to work toward the shared goal of advancing next generation precision radiopharmaceuticals for patients with hard-to-treat cancers.”

 

Financially, the deal includes an upfront $40 million cash payment from Regeneron to Telix for access to its radiopharmaceutical manufacturing platform across four initial programs. Regeneron has the option to expand the collaboration to four additional programs, each with additional upfront payments.

 

The companies will share global development costs and profits equally, while Telix retains the option to co-promote selected products. If Telix opts out of co-funding a given program, it could instead receive up to $535 million in development and commercial milestones, along with low double-digit royalties on net sales.

 

The partnership also includes joint development of diagnostic assets, with Telix taking the lead on commercialization and Regeneron receiving a share of resulting profits.